Testing a new drug combo for untreated advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new drug called Serplulimab given with chemotherapy and aspirin for people with extensive-stage small cell lung cancer who have not had treatment yet. The goal is to see if the combination is safe and works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You have not received any previous treatment for this stage of lung cancer.
- You have at least one tumor that can be measured on a CT scan or PET-CT scan.
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.